<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2023.1082423</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Machine learning in non-small cell lung cancer radiotherapy: A bibliometric analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Jiaming</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1899100"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Huijun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/709186"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Jue</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1316614"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Yulu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2223175"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Yihe</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2223169"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Xinyu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2223159"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Menghua</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cai</surname>
<given-names>Zhengwen</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Liu</surname>
<given-names>Wenqi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/855317"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Radiation Oncology, The Second Affiliated Hospital of Guangxi Medical University</institution>, <addr-line>Nanning</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Oncology, The Second Affiliated Hospital of Guangxi Medical University</institution>, <addr-line>Nanning</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Tonghe Wang, Memorial Sloan Kettering Cancer Center, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Li-Sheng Geng, Beihang University, China; Jian Bin Li, Shandong Cancer Hospital, China</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Zhengwen Cai, <email xlink:href="mailto:99cczzww@sina.com">99cczzww@sina.com</email>; Wenqi Liu, <email xlink:href="mailto:liuwenqigx@163.com">liuwenqigx@163.com</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work and share first authorship</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Radiation Oncology, a section of the journal Frontiers in Oncology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>17</day>
<month>03</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>13</volume>
<elocation-id>1082423</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>10</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>20</day>
<month>02</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Zhang, Zhu, Wang, Chen, Li, Chen, Chen, Cai and Liu</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Zhang, Zhu, Wang, Chen, Li, Chen, Chen, Cai and Liu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Machine learning is now well-developed in non-small cell lung cancer (NSCLC) radiotherapy. But the research trend and hotspots are still unclear. To investigate the progress in machine learning in radiotherapy NSCLC, we performed a bibliometric analysis of associated research and discuss the current research hotspots and potential hot areas in the future.</p>
</sec>
<sec>
<title>Methods</title>
<p>The involved researches were obtained from the Web of Science Core Collection database (WoSCC). We used R-studio software, the Bibliometrix package and VOSviewer (Version 1.6.18) software to perform bibliometric analysis.</p>
</sec>
<sec>
<title>Results</title>
<p>We found 197 publications about machine learning in radiotherapy for NSCLC in the WoSCC, and the journal Medical Physics contributed the most articles. The University of Texas MD Anderson Cancer Center was the most frequent publishing institution, and the United States contributed most of the publications. In our bibliometric analysis, &#x201c;radiomics&#x201d; was the most frequent keyword, and we found that machine learning is mainly applied to analyze medical images in the radiotherapy of NSCLC.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>The research we identified about machine learning in NSCLC radiotherapy was mainly related to the radiotherapy planning of NSCLC and the prediction of treatment effects and adverse events in NSCLC patients who were under radiotherapy. Our research has added new insights into machine learning in NSCLC radiotherapy and could help researchers better identify hot research areas in the future.</p>
</sec>
</abstract>
<kwd-group>
<kwd>non-small cell lung cancer</kwd>
<kwd>radiotherapy</kwd>
<kwd>machine learning</kwd>
<kwd>computer science</kwd>
<kwd>bibliometric analysis</kwd>
</kwd-group>
<counts>
<fig-count count="7"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="45"/>
<page-count count="10"/>
<word-count count="3910"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Lung cancer is one of the most common malignant tumors (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). According to <italic>Cancer Statistics, 2020</italic>, the 5-year survival rate of lung cancer is only 19% (<xref ref-type="bibr" rid="B1">1</xref>). Non-small cell lung cancer (NSCLC) is defined as a subtype of lung cancer that accounts for over 80% of lung cancer cases (<xref ref-type="bibr" rid="B3">3</xref>). Although there are many treatments for NSCLC, the long-term survival rate of advanced NSCLC patients is still poor (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>).</p>
<p>Radiotherapy is part of the treatment of almost all stages of NSCLC. Approximately 30% of NSCLC patients are diagnosed with unresectable stage III cancer, also called locally advanced NSCLC (<xref ref-type="bibr" rid="B6">6</xref>). The standard treatment for unresectable stage III NSCLC patients is concurrent chemoradiotherapy according to the NCCN guidelines (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). Stereotactic body radiotherapy (SBRT) is widely used in the treatment of patients with early-stage unresectable NSCLC. In addition, palliative radiotherapy is also recommended in patients with advanced or progressive NSCLC. However, problems such as target delineation, dose and fractionated irradiation mode still trouble clinicians (<xref ref-type="bibr" rid="B9">9</xref>&#x2013;<xref ref-type="bibr" rid="B12">12</xref>). Manual contouring of target volumes and organs at risk (OARs) is an important process for radiotherapy planning. These tasks may be repetitive and time-consuming. Furthermore, some questions, such as which kind of patients can benefit more from radiotherapy and when is the optimal time to receive radiotherapy, are still in dispute (<xref ref-type="bibr" rid="B13">13</xref>). Therefore, it is necessary to reduce the burden of clinicians and improve the efficacy of radiotherapy.</p>
<p>Researchers are now exploring the use of machine learning in radiotherapy (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>). Machine learning is a multidisciplinary interdisciplinary field that involves statistics, convex analysis, probability theory, approximation theory, and algorithm complexity theory. Today, hundreds of articles on machine learning in NSCLC radiotherapy have been published. These articles span research areas such as radiotherapy planning, prognosis prediction, adverse event prediction and clinical decisions. Keeping an eye on the most influential articles and the research hotspots is important to researchers. Therefore, it is necessary to comprehensively analyze and summarize the current research trends and hotspots of machine learning in radiotherapy for NSCLC.</p>
<p>Bibliometric analysis aims to analyze the annual volume of articles and journals, countries, and regions using the database of citation reports. In addition, it can also expose hot topics and potential research directions of annual research so that researchers can better understand the current research trends and hot spots in the research field. We performed a bibliometric analysis on machine learning in radiotherapy for NSCLC. We highlighted the research progress and research trend of machine learning in radiotherapy for NSCLC. We comprehensively analyzed relevant publications and provide references for further research on machine learning in radiotherapy for NSCLC.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Method</title>
<sec id="s2_1">
<label>2.1</label>
<title>Database and systematic search strategy</title>
<p>We obtained citation reports using the core collection of the Web of Science database (WoSCC). We searched all articles on machine learning in radiation therapy for NSCLC. The time limit for the included studies was from the inception of WoSCC to August 31, 2022. In our process of study screening, the only type of publication we included was article. We excluded review articles, meeting abstracts, proceeding papers and early access. The search strategies and inclusion criteria are listed in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>The search strategies of our bibliometric analysis, TS: Topic, which includes title, abstract, author keywords and additional keywords.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1082423-g001.tif"/>
</fig>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Statistical analysis</title>
<p>We used R-studio software, the Bibliometrix package and VOSviewer (Version 1.6.18) software to analyze the collected data and Biblioshiny to visualize the data. The Bibliometrix package is a kind of workflow for performing bibliometric analysis and was programmed by R (<xref ref-type="bibr" rid="B16">16</xref>). Then, we analyzed the number of publications, citations and collaborations, annual publications and author publications in a country/region. We also analyzed the quality of the author&#x2019;s academic production using the H-index. It was defined that if the scientist has index h, there are at least h citations (N<sub>P</sub> &#x2013; h) between the papers whose index is hN<sub>p</sub>, and each paper has &#x2264; h citations (<xref ref-type="bibr" rid="B17">17</xref>). Then, we analyzed the hotspots of machine learning in NSCLC radiotherapy and the annual trend topics. We constructed the keyword co-occurrence network using VOSviewer. Different clusters in a network diagram are represented by different colors, and collaborations, cooccurrence, are represented by connectors. The thickness of the connecting line indicates the strength of the association. The size of the circle indicates the number of publications, references, or keywords.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>Annual publication analysis</title>
<p>We found 197 publications about machine learning in radiotherapy for NSCLC in the WoS core database, and the data generated by the WoS database are listed in the <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary material</bold>
</xref>. We obtained all the publications we found for bibliometric analysis. The overall trend of annual publications is shown in <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>. These results indicate that machine learning in radiotherapy is still an important frontier field in the treatment of NSCLC patients.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Annual publications about machine learning in NSCLC radiotherapy.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1082423-g002.tif"/>
</fig>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Bibliometric analysis of top journals</title>
<p>The articles included in the bibliometric analysis were from a total of 72 journals. In our analysis, the journal <italic>Medical Physics</italic> contributed the most articles at 22 and accounting for 11% of the total articles. According to Bradford&#x2019;s Law, most of the articles are from <italic>Medical Physics</italic>, <italic>Radiotherapy and Oncology, Frontiers in Oncology, Scientific Reports</italic> and <italic>International Journal of Radiation Oncology</italic>. The most frequently cited journal is <italic>International Journal of Radiation Oncology</italic>, with a total of 717 local citations, followed by <italic>Radiother Oncol</italic> and <italic>Medical Physics</italic>, with a total of 12 journals cited more than 100 times. The results are shown in <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>
<bold>(A)</bold> The top 10 most locally cited journals in the bibliometric analysis. <bold>(B)</bold> The top 10 most published journals in bibliometric analysis. <bold>(C)</bold> The core sources of bibliometric analysis according to Bradford&#x2019;s law.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1082423-g003.tif"/>
</fig>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Bibliometric analysis of authors, institutions and countries/regions</title>
<p>The included articles are from 1350 different authors. The author with the most published articles is Lambin P from the Maastricht University Medical Center, who has participated in the publication of 20 included articles, followed by El Naqa I and Dekker A. The author with the most local citations is Aerts HJWL, who with a total of 61 local citations. According to the author&#x2019;s influence calculated by the H-index, Lambin P has the highest influence, followed by El Naqa I and Leijennar Rth. We also analyzed the coauthor relationship and constructed the coauthor network. The results are shown in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>
<bold>(A)</bold> The top 10 most published authors in the bibliometric analysis. <bold>(B)</bold> The top 10 most local cited authors in bibliometric analysis. <bold>(C)</bold> The H-index of authors in bibliometric analysis. <bold>(D)</bold> The co-authorship in bibliometric analysis.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1082423-g004.tif"/>
</fig>
<p>The included articles were from a total of 380 institutions. Eleven institutions had more than 10 publications. The University of Texas MD Anderson Cancer Center was the most frequent publishing institution, contributing 35 articles. Then, we analyzed the cooperative relationship among institutions. Bibliometric analysis for national/regional published research is also essential. The articles included are from 16 different countries or regions. The United States has published the most articles, with 65 articles in total, followed by China and Netherlands. The results are shown in <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>
<bold>(A)</bold> The most published institution in bibliometric analysis. <bold>(B)</bold> The cooperative relationship of institutions in bibliometric analysis. <bold>(C)</bold> Country publications. MCP: Multicenter publishing, SCP: Single-center publishing. <bold>(D)</bold> The annual publication by country.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1082423-g005.tif"/>
</fig>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Bibliometric analysis of citations and references</title>
<p>Citation analysis revealed that a total of 13 articles were cited more than 100 times. The article by Silvia C Formenti published in 2018, <italic>Radiotherapy induces responses of lung cancer to CTLA-4 blockade</italic>, has the most global citations. Then, we analyzed the references of the included publications. We found that the most cited reference was <italic>Radiomics: extracting more information from medical images using advanced feature analysis</italic> from Philippe Lambin, which has been cited 49 times. The results are shown in <xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6</bold>
</xref>.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>
<bold>(A)</bold> The most globally cited articles in bibliometric analysis. <bold>(B)</bold> The most locally cited references in bibliometric analysis.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1082423-g006.tif"/>
</fig>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>Bibliometric analysis of keywords</title>
<p>To analyze the current research hotspots and trends, the keywords were analyzed. We used Vosviewer and Bibliometrix to analyze the co-occurrence keywords included in the dataset. There were 434 author keywords in total, of which 9 appeared more than 10 times. The top three keywords were &#x201c;radiomics&#x201d;, &#x201c;non-small cell lung cancer&#x201d; and &#x201c;lung cancer&#x201d;. Then, we used Vosviewer to visualize the co-occurrence keyword network. The results are shown in <xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7</bold>
</xref>, and the keywords are listed in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>.</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>
<bold>(A)</bold> The most frequent keywords in bibliometric analysis. <bold>(B)</bold> Keyword co-occurrence analysis in bibliometric analysis. <bold>(C)</bold> Density map of keyword analysis. <bold>(D)</bold> Thematic map through keyword analysis.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1082423-g007.tif"/>
</fig>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>The top 10 most frequent keywords in bibliometric analysis.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="bottom" align="left">Words</th>
<th valign="bottom" align="center">Occurrences</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="bottom" align="left">radiomics</td>
<td valign="bottom" align="center">50</td>
</tr>
<tr>
<td valign="bottom" align="left">non-small cell lung cancer</td>
<td valign="bottom" align="center">33</td>
</tr>
<tr>
<td valign="bottom" align="left">lung cancer</td>
<td valign="bottom" align="center">31</td>
</tr>
<tr>
<td valign="bottom" align="left">machine learning</td>
<td valign="bottom" align="center">25</td>
</tr>
<tr>
<td valign="bottom" align="left">NSCLC</td>
<td valign="bottom" align="center">21</td>
</tr>
<tr>
<td valign="bottom" align="left">radiotherapy</td>
<td valign="bottom" align="center">19</td>
</tr>
<tr>
<td valign="bottom" align="left">computed tomography</td>
<td valign="bottom" align="center">11</td>
</tr>
<tr>
<td valign="bottom" align="left">radiation pneumonitis</td>
<td valign="bottom" align="center">11</td>
</tr>
<tr>
<td valign="bottom" align="left">deep learning</td>
<td valign="bottom" align="center">10</td>
</tr>
<tr>
<td valign="bottom" align="left">positron emission tomography</td>
<td valign="bottom" align="center">9</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>We used the Bibliomtrix package to construct a thematic map through the bibliometric analysis of keywords. The thematic map was divided into 4 quadrants. The first quadrant is the motor themes, which represent important and well-developed topics. The second quadrant is the highly developed and isolated themes, which represent well-developed but not very important recent topics. The third quadrant is the emerging or disappearing themes, which represent those topics that may have just emerged or may soon disappear. The fourth quadrant is basic themes, which represent those topics that are very important to the field but have not been well developed. The bubble size depends on the occurrence frequency of cluster keywords. The bubble location depends on the development degree and relevance degree of the clusters (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B18">18</xref>). In our research, there are three clusters located in the first quadrant, and the keywords &#x201c;deep learning&#x201d; and &#x201c;convolutional neural network&#x201d; and &#x201c;dosiomics&#x201d; and &#x201c;computer-assisted image analysis&#x201d; could be considered the current research frontiers. &#x201c;Radiomics&#x201d; and &#x201c;machine learning&#x201d; may be the basis of current research on machine learning in NSCLC radiotherapy. The results are shown in <xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7</bold>
</xref>.</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>Radiotherapy is one of the main treatment methods for locally advanced or advanced NSCLC, and it still has rich research value at present (<xref ref-type="bibr" rid="B19">19</xref>&#x2013;<xref ref-type="bibr" rid="B22">22</xref>). Machine learning is also one of the research hot fields in the radiotherapy of NSCLC. Although a large number of relevant studies on machine learning in radiotherapy for NSCLC emerge every year, there is still a lack of corresponding bibliometric analysis to summarize the research trends and current hotspots of machine learning in radiotherapy for NSCLC. In our study, we used the Bibliometrix package and Vosviewer software to perform a bibliometric analysis of machine learning in NSCLC radiotherapy.</p>
<p>The studies on machine learning in NSCLC radiotherapy that we included in the bibliometric analysis were mainly about several subjects as discussed below.</p>
<sec id="s4_1">
<label>4.1</label>
<title>Machine learning in NSCLC radiotherapy planning</title>
<p>Radiotherapy planning is one of the most important steps in NSCLC radiotherapy. In the research that we analyzed, machine learning mainly participated in radiotherapy planning, dosimetric assessment, delineation of tumor volumes and OARs of NSCLC radiotherapy. Volumetric modulated arc therapy (VMAT) is one of the treatments for locally advanced NSCLC. Giuseppe Della Gala&#x2019;s team developed an autoVMAT treatment planning system for NSCLC using data from a previous patient database. The autoVMAT planning system showed statistically significant improvements in planning target volume (PTV) coverage, with an increase in V95% of 1.1% &#xb1; 1.1%, and higher dose conformity, with a reduction in R50 of 12.2% &#xb1; 12.7%, when compared to manually created intensity-modulated radiation therapy (IMRT) plans. Additionally, the autoVMAT planning system also reduced the mean doses of organs at risk (OARs) including lung, heart, and esophagus with reductions of 0.9&#x2009;Gy &#xb1; 1.0&#x2009;Gy, 1.5&#x2009;Gy &#xb1; 1.8&#x2009;Gy, and 3.6&#x2009;Gy &#xb1; 2.8&#x2009;Gy, respectively (p &lt; 0.001) (<xref ref-type="bibr" rid="B23">23</xref>). In dosimetric assessment, automated dose adaptation based on deep reinforcement learning was also a potential research hotspot. Huan&#x2010;Hsin Tseng have constructed an automated radiation adaptation protocols based on multicomponent reinforcement learning for deep learning. Then, they chose the optimal dose generated by the trained model. Their results considered that automated dose adaptation could achieve similar results to those chosen by clinical doctors(the estimated root&#x2010;mean&#x2010;square error (RMSE)&#x2248;0.76 Gy when compared to the clinical data) (<xref ref-type="bibr" rid="B24">24</xref>). Besides, delineation of tumor volumes and organs at risk such as esophagus, heart and aorta on medical images is important but time-consuming. A recent study compared the performance between automatic segmentation of OARs based on a convolutional neural network (AS-CNN) and atlas (AS-Atlas). The results showed that both AS-CNN and AS-Atlas could reduce substantial time for OAR segmentations when compared to manual delineation (the average time of AS-CNN and AS-Atlas was 1.6&#x200a;minutes and 2.4&#x200a;minutes when manual delineation costed 25.4&#x200a;minutes). And the accuracy of auto segmentation of OARs was similar to manual delineation (<xref ref-type="bibr" rid="B25">25</xref>). Furthermore, the analysis of single-modality medical images may lack some important information, as they only partially reflect the tumor&#x2019;s characteristics and may reduce the accuracy of tumor volume and OARs delineation. Therefore, recent research has focused on multimodal medical image analysis to improve the accuracy and effectiveness of tumor segmentation. Jue Jiangs presented a cross-modality model based on data from CT and MRI images for deep learning lung tumor segmentation. They transformed the CT images to MR images resembling T2w MRI. And then they performed the auto segmentation through the deep learning model base on the data from CT scanning and expert-segmented T2w MR. The tumor segmentation generated by this model was proven to be highly similar to expert segmentation (Dice similarity coefficient (DSC)= 0.75 &#xb1; 0.12) (<xref ref-type="bibr" rid="B26">26</xref>).</p>
</sec>
<sec id="s4_2">
<label>4.2</label>
<title>Machine learning in NSCLC radiotherapy efficacy evaluation</title>
<p>Although radiotherapy is an important treatment for unresectable NSCLC, the response to radiation within different NSCLC patients exhibits wide heterogeneity. Some NSCLC patients have long-term control after receiving radiotherapy, while others relapse or metastasize despite receiving a high dose of radiation (<xref ref-type="bibr" rid="B27">27</xref>). Thus, it is important to evaluate the efficacy of radiotherapy for NSCLC patients, including short-term efficacy and long-term efficacy. For short-term efficacy, Lameck Mbangula Amugongo has developed an automatic method through cone beam computed tomography (CBCT) images. And they constructed 4 models (linear, Gaussian, quadratic and cubic methods) that could predict the tumor volume and shape in weeks 3 and 4 of radiotherapy. And results showed that the linear model performed best at predicting tumor volume changes with a sensitivity of 84% and specificity of 99% (<xref ref-type="bibr" rid="B28">28</xref>). Besides, researchers also presented a prediction model based on radiomic phenotype features. This model could predict the tumor pathological response after neoadjuvant chemoradiation in NSCLC patients, particularly in pathologic gross residual disease and pathologic complete response (<xref ref-type="bibr" rid="B29">29</xref>). For long-term efficacy, a recent multicentric study developed a radiomics predictive model that could predict local relapse in NSCLC patients treated with SBRT. The model was based on radiomics from the PET/CT features, and the results of the study revealed that the area under curve (AUC) of model combining 2 PET feature has reached 0.94, and the sensitivity=100%; specificity=88% (<xref ref-type="bibr" rid="B30">30</xref>). In addition, to improve the performance of the prediction model, researchers presented a model based on multiple factors, which included CT imaging and clinical and hematological features. The results showed that the multifactor prediction model performed better than radiomic, clinical, or hematological models alone for survival prediction of patients with locally advanced NSCLC (<xref ref-type="bibr" rid="B31">31</xref>). However, many studies have investigated the prognostic factors from medical images by identifying the optimum value or a cutoff value from the continuous values of the image-derived index, and this method is called the &#x2018;optimum cutoff approach&#x2019;. Then, researchers divided the patients into a high-risk group or a low-risk group based on the cutoff value. However, a systematic review revealed that the use of the optimum cutoff approach may lead to type-I errors. In addition, this review also reported that the texture features extracted from PET and CT images represented a positive patient prognosis in some studies but a negative prognosis in other studies. Thus, researchers considered that the conclusions conflicted and evidence was insufficient to support a relationship between patient prognosis and features extracted from CT and PET (<xref ref-type="bibr" rid="B32">32</xref>).</p>
</sec>
<sec id="s4_3">
<label>4.3</label>
<title>Machine learning in NSCLC radiotherapy adverse event prediction</title>
<p>Prediction of radiation-induced adverse events through machine learning is also one of the hotspots of current research. Radiation pneumonitis is one of the most common and important adverse events of patients who receive radiotherapy, with an incidence of 29% in some studies (<xref ref-type="bibr" rid="B33">33</xref>). Jos&#xe9; Marcio Luna reported that lung V20 (the percentage of the total lung volume that receives a radiation dose of 20 Gy or higher)&gt; 27.4%, lung mean dose &gt;15.4 Gy, lung V10 &gt;36.3% and lung V5 &gt;43.6% were the predictor of radiation pneumonitis in univariate analysis. And their multivariate analysis based on random forest method also revealed that esophagus max, lung V20, lung mean and pack-year as the predictor of radiation pneumonitis (AUC=0.66) (<xref ref-type="bibr" rid="B34">34</xref>). In addition, radiation-induced esophagitis was also frequent in patients who receive chest radiation. A recently published study compared the predictive performance of different modeling methods in radiation-induced esophagitis. The researcher reported that the least absolute shrinkage and selection operator (LASSO-MLR) performed best in radiation-induced esophagitis prediction (AUC=0.79) (<xref ref-type="bibr" rid="B35">35</xref>). Furthermore, differentiation between radiation pneumonitis and immune checkpoint inhibitor (ICI)-induced pneumonitis is also very important when radiotherapy is combined with ICI treatment. Jun Cheng constructed a model that could identify patients with radiation pneumonitis or ICI-caused pneumonitis based on radiological characteristics using machine learning, and achieving an AUC of 0.896 (<xref ref-type="bibr" rid="B36">36</xref>). The adverse events of tumor radiotherapy are closely related to the radiation dose. It was reported that lung V5, V20, and V30 were closely associated with the incidence of radiation pneumonitis in chest radiotherapy (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>). To enhance the accuracy of predicting radiation pneumonitis, researchers are investigating the use of dosiomics, a novel concept emerged in recent years. Dosiomics can extract the dose distribution characteristics in the radiotherapy plan (<xref ref-type="bibr" rid="B39">39</xref>). And a recent study predicted the incidence of radiation pneumonitis through dosiomics. Researchers constructed the model based on dosiomics for predicting the incidence of radiation pneumonitis. They reported that the AUC of dosiomics prediction model based on multivariate logistic regression was 0.782 and performed better than the dosimetric factors(mean dose of ipsilateral lung and contralateral lung V5, AUC=0.676) (<xref ref-type="bibr" rid="B40">40</xref>).</p>
</sec>
<sec id="s4_4">
<label>4.4</label>
<title>The limitation of included studies</title>
<p>Although machine learning has been widely reported to be involved in NSCLC radiotherapy planning, efficacy prediction, and adverse reaction assessment in clinical practice, there are still some limitations in current studies. Firstly, most of the included studies were based on data analysis from single center, with small sample sizes and a lack of external validation. These issues may lead to a decrease in the efficacy of the predictive model, make it unsuitable for different populations, and result in false research findings (<xref ref-type="bibr" rid="B41">41</xref>). Secondly, many of the studies we included were retrospective studies and lack of prospective studies. The data they used to train and validate the prediction models came from patients who had already received treatment and had known outcomes. That may increase the risk of reporting biased. Thirdly, the radiomics prediction models rely on quantitative imaging features extracted from medical images (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>). Which can be influenced by scanning devices, different acquisition modes and reconstruction parameters (<xref ref-type="bibr" rid="B32">32</xref>). The limitation hinders the development of universal imaging radiomics models. While there have been numerous studies on the application of machine learning in NSCLC radiotherapy, the current research still has certain limitations in terms of depth or effectiveness. To address these limitations, the following potential research hotspots should be considered.</p>
</sec>
<sec id="s4_5">
<label>4.5</label>
<title>Future hotspots of machine learning in NSCLC radiotherapy</title>
<p>Our research was based on 197 articles published from 2000 to 2022. According to recently published articles and the discussion among the authors, the future hotspots of machine learning in NSCLC radiotherapy are as follows:</p>
<list list-type="simple">
<list-item>
<p>1) Improve the accuracy of data analysis and model construction and reduce misdiagnoses or missed diagnoses. There is a common denominator in most machine learning models: the more data used to train the model, the better it will perform (<xref ref-type="bibr" rid="B43">43</xref>). Therefore, machine learning models based on multicenter data may be a future research focus of NSCLC radiotherapy.</p>
</list-item>
<list-item>
<p>2) Machine learning-based clinical decision support system for individualized treatment. In the precision medicine era, precision and individualized radiotherapy is more suitable for patients. In the past, clinical decisions were made by clinical experts. Recently, clinical decision support systems (CDSSs) were considered that could lead to the development of precision and individualized radiotherapy (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>). This kind of system will provide suggestions to clinicians and help them make decisions on and plan patients&#x2019; treatment.</p>
</list-item>
<list-item>
<p>3) Multiple clinical factors prediction model. Prediction models based on radiomics occupied most of our included studies. However, a multiple clinical factors prediction model was reported to be better than radiomics alone in outcome prediction (<xref ref-type="bibr" rid="B31">31</xref>). In the era of precision treatment, clinicians may provide individualized treatment based on the predictive outcomes of patients. Therefore, it may be disastrous to incorrectly predict the outcomes of patients with NSCLC. Thus, in the future, prediction models based on multiple clinical factors will be a research hotspot.</p>
</list-item>
</list>
</sec>
</sec>
<sec id="s5">
<label>5</label>
<title>Limitations of our analysis</title>
<list list-type="simple">
<list-item>
<p>1) Due to the limitations of bibliometric analysis software and visualization software, it is difficult to merge and analyze data from different databases (such as PubMed, Embase, Cochrane Library), which limits the comprehensiveness of the analysis.</p>
</list-item>
<list-item>
<p>2) We only included English articles, which will lead to a selective bias.</p>
</list-item>
<list-item>
<p>3) The included articles were published from database inception to August 31, 2022. However, the database is still being updated, and we failed to include most recent publications. This may affect the results of the analysis.</p>
</list-item>
</list>
</sec>
<sec id="s6" sec-type="conclusions">
<label>6</label>
<title>Conclusion</title>
<p>Radiotherapy for NSCLC is widely used, and machine learning is widely used in NSCLC radiotherapy. However, compared with the number of studies on radiotherapy for NSCLC, the number of studies related to machine learning in radiotherapy for NSCLC is still small. Further studies in these areas are needed to benefit patients. Therefore, it is necessary to analyze the relevant studies and determine the possible research directions and hotspots. In conclusion, our bibliometric analysis analyzed the research trends, hotspots and other information. This could help researchers to further study the fields of machine learning in NSCLC radiotherapy.</p>
</sec>
<sec id="s7" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s8" sec-type="author-contributions">
<title>Author contributions</title>
<p>WL and ZC contributed to the conception of the study, and supervision. YL and XC contributed to the collection of data. YC and MC contributed to statistics of research data and the arrangement of research pictures. JZ and HZ performed the bibliometric analysis and wrote the manuscript, should be considered as the co-first author. HZ and JW helped to perform the analysis with constructive discussions and editing. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>The authors declare that this study received funding from Guangxi key research and development program No. (GK) AB18221080, The Basic Ability Enhancement Program for Young and Middle-aged Teachers of Guangxi (2020KY03036), Youth Foundation of Guangxi Medical University(GXMUYSF201918), Foundation of Guangxi Health and Family Planning Commission (Z20190581), Foundation of the Second Affiliate Hospital of Guangxi Medical University (hbrc202104). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>Many people have participated in this study and offered their help in the manuscript writing. Firstly, Thanks are due to professor WL and ZC for the conception of the study, supervision and discussion of the results. And we also thank all the staff of Department of Radiation Oncology, The Second Affiliated Hospital of Guangxi Medical University for providing suggestions for writing manuscript.</p>
</ack>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s12" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fonc.2023.1082423/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2023.1082423/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Table_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siegel</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>KD</given-names>
</name>
<name>
<surname>Jemal</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Cancer statistics, 2020</article-title>. <source>CA: Cancer J Clin</source> (<year>2020</year>) <volume>70</volume>(<issue>1</issue>):<fpage>7</fpage>&#x2013;<lpage>30</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3322/caac.21590</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bray</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ferlay</surname> <given-names>J</given-names>
</name>
<name>
<surname>Soerjomataram</surname> <given-names>I</given-names>
</name>
<name>
<surname>Siegel</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Torre</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Jemal</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA: Cancer J Clin</source> (<year>2018</year>) <volume>68</volume>(<issue>6</issue>):<fpage>394</fpage>&#x2013;<lpage>424</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3322/caac.21492</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duma</surname> <given-names>N</given-names>
</name>
<name>
<surname>Santana-Davila</surname> <given-names>R</given-names>
</name>
<name>
<surname>Molina</surname> <given-names>JR</given-names>
</name>
</person-group>. <article-title>Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment</article-title>. <source>Mayo Clinic Proc</source> (<year>2019</year>) <volume>94</volume>(<issue>8</issue>):<page-range>1623&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.mayocp.2019.01.013</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arbour</surname> <given-names>KC</given-names>
</name>
<name>
<surname>Riely</surname> <given-names>GJ</given-names>
</name>
</person-group>. <article-title>Systemic therapy for locally advanced and metastatic non-small cell lung cancer: A review</article-title>. <source>JAMA</source> (<year>2019</year>) <volume>322</volume>(<issue>8</issue>):<page-range>764&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1001/jama.2019.11058</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Panda</surname> <given-names>GS</given-names>
</name>
<name>
<surname>Noronha</surname> <given-names>V</given-names>
</name>
<name>
<surname>Shah</surname> <given-names>D</given-names>
</name>
<name>
<surname>John</surname> <given-names>G</given-names>
</name>
<name>
<surname>Chougule</surname> <given-names>A</given-names>
</name>
<name>
<surname>Patil</surname> <given-names>V</given-names>
</name>
<etal/>
</person-group>. <article-title>Treatment pattern and outcomes in <italic>De novo</italic> T790m-mutated non-small cell lung cancer</article-title>. <source>Ecancermedicalscience</source> (<year>2022</year>) <volume>16</volume>:<elocation-id>1385</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3332/ecancer.2022.1385</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morgensztern</surname> <given-names>D</given-names>
</name>
<name>
<surname>Ng</surname> <given-names>SH</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>F</given-names>
</name>
<name>
<surname>Govindan</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Trends in stage distribution for patients with non-small cell lung cancer: A national cancer database survey</article-title>. <source>J Thorac Oncol</source> (<year>2010</year>) <volume>5</volume>(<issue>1</issue>):<fpage>29</fpage>&#x2013;<lpage>33</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/JTO.0b013e3181c5920c</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>Nccn Guidelines</collab>
</person-group>. <source>Non-small cell lung cancer version 1</source> (<year>2022</year>). Available at: <uri xlink:href="https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1450">https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1450</uri>.</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Antonia</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Villegas</surname> <given-names>A</given-names>
</name>
<name>
<surname>Daniel</surname> <given-names>D</given-names>
</name>
<name>
<surname>Vicente</surname> <given-names>D</given-names>
</name>
<name>
<surname>Murakami</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hui</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Durvalumab after chemoradiotherapy in stage iii non-Small-Cell lung cancer</article-title>. <source>New Engl J Med</source> (<year>2017</year>) <volume>377</volume>(<issue>20</issue>):<page-range>1919&#x2013;29</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa1709937</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname> <given-names>J</given-names>
</name>
<name>
<surname>Han</surname> <given-names>C</given-names>
</name>
<name>
<surname>Jackson</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer</article-title>. <source>Radiotherapy Oncol</source> (<year>2019</year>) <volume>133</volume>:<page-range>213&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.radonc.2018.10.029</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>T</given-names>
</name>
<name>
<surname>Li</surname> <given-names>M</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: Current clinical trials and prospective challenges</article-title>. <source>Precis Clin Med</source> (<year>2019</year>) <volume>2</volume>(<issue>1</issue>):<fpage>57</fpage>&#x2013;<lpage>70</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/pcmedi/pbz004</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>R</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Gui</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>BQ</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting myeloid-derived suppressor cells and programmed death ligand 1 confers therapeutic advantage of ablative hypofractionated radiation therapy compared with conventional fractionated radiation therapy</article-title>. <source>Int J Radiat oncology biology Phys</source> (<year>2018</year>) <volume>101</volume>(<issue>1</issue>):<fpage>74</fpage>&#x2013;<lpage>87</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2018.01.071</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aryankalayil</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Makinde</surname> <given-names>AY</given-names>
</name>
<name>
<surname>Gameiro</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Hodge</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Rivera-Solis</surname> <given-names>PP</given-names>
</name>
<name>
<surname>Palayoor</surname> <given-names>ST</given-names>
</name>
<etal/>
</person-group>. <article-title>Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells</article-title>. <source>Radiat Res</source> (<year>2014</year>) <volume>182</volume>(<issue>2</issue>):<page-range>139&#x2013;48</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1667/rr13731.1</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>S</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>X</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>The critical components for effective adaptive radiotherapy in patients with unresectable non-Small-Cell lung cancer: Who, when and how</article-title>. <source>Future Oncol</source> (<year>2022</year>), <volume>18</volume>(<issue>31</issue>):<page-range>3551&#x2013;3562</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2217/fon-2022-0291</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname> <given-names>J</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>V</given-names>
</name>
<name>
<surname>Wells</surname> <given-names>D</given-names>
</name>
<name>
<surname>Giambattista</surname> <given-names>J</given-names>
</name>
<name>
<surname>Giambattista</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kolbeck</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Implementation of deep learning-based auto-segmentation for radiotherapy planning structures: A workflow study at two cancer centers</article-title>. <source>Radiat Oncol (London England)</source> (<year>2021</year>) <volume>16</volume>(<issue>1</issue>):<fpage>101</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13014-021-01831-4</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jarrett</surname> <given-names>D</given-names>
</name>
<name>
<surname>Stride</surname> <given-names>E</given-names>
</name>
<name>
<surname>Vallis</surname> <given-names>K</given-names>
</name>
<name>
<surname>Gooding</surname> <given-names>MJ</given-names>
</name>
</person-group>. <article-title>Applications and limitations of machine learning in radiation oncology</article-title>. <source>Br J Radiol</source> (<year>2019</year>) <volume>92</volume>(<issue>1100</issue>):<elocation-id>20190001</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1259/bjr.20190001</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aria</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cuccurullo</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Bibliometrix: An r-tool for comprehensive science mapping analysis</article-title>. <source>J Informetrics</source> (<year>2017</year>) <volume>11</volume>(<issue>4</issue>):<page-range>959&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.joi.2017.08.007</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirsch</surname> <given-names>JE</given-names>
</name>
</person-group>. <article-title>An index to quantify an individual's scientific research output</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2005</year>) <volume>102</volume>(<issue>46</issue>):<page-range>16569&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.0507655102</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="web">
<source>The home page of bibliometrix</source>. Available at: <uri xlink:href="https://www.bibliometrix.org/home/">https://www.bibliometrix.org/home/</uri>.</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoenfeld</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Giobbie-Hurder</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ranasinghe</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kao</surname> <given-names>KZ</given-names>
</name>
<name>
<surname>Lako</surname> <given-names>A</given-names>
</name>
<name>
<surname>Tsuji</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-Small-Cell lung cancer refractory to previous Pd(L)-1 therapy: An open-label, multicentre, randomised, phase 2 trial</article-title>. <source>Lancet Oncol</source> (<year>2022</year>) <volume>23</volume>(<issue>2</issue>):<page-range>279&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s1470-2045(21)00658-6</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spigel</surname> <given-names>DR</given-names>
</name>
<name>
<surname>Faivre-Finn</surname> <given-names>C</given-names>
</name>
<name>
<surname>Gray</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Vicente</surname> <given-names>D</given-names>
</name>
<name>
<surname>Planchard</surname> <given-names>D</given-names>
</name>
<name>
<surname>Paz-Ares</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Five-year survival outcomes from the pacific trial: Durvalumab after chemoradiotherapy in stage iii non-Small-Cell lung cancer</article-title>. <source>J Clin Oncol</source> (<year>2022</year>) <volume>40</volume>(<issue>12</issue>):<page-range>1301&#x2013;11</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1200/jco.21.01308</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gupta</surname> <given-names>R</given-names>
</name>
<name>
<surname>Singh</surname> <given-names>TP</given-names>
</name>
<name>
<surname>Jakhar</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Sharma</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kumar</surname> <given-names>HS</given-names>
</name>
</person-group>. <article-title>A comparative study of concurrent chemo-radiotherapy with or without neoadjuvant chemotherapy in treatment of locally advanced non small cell lung cancer</article-title>. <source>Gulf J Oncol</source> (<year>2021</year>) <volume>1</volume>(<issue>37</issue>):<page-range>62&#x2013;9</page-range>.</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Contreras</surname> <given-names>J</given-names>
</name>
<name>
<surname>Srivastava</surname> <given-names>A</given-names>
</name>
<name>
<surname>Samson</surname> <given-names>P</given-names>
</name>
<name>
<surname>DeWees</surname> <given-names>T</given-names>
</name>
<name>
<surname>Govindan</surname> <given-names>R</given-names>
</name>
<name>
<surname>Baggstrom</surname> <given-names>MQ</given-names>
</name>
<etal/>
</person-group>. <article-title>Phase I study of accelerated hypofractionated proton therapy and chemotherapy for locally advanced non-small cell lung cancer</article-title>. <source>Int J Radiat oncology biology Phys</source> (<year>2022</year>) <volume>113</volume>(<issue>4</issue>):<page-range>742&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2022.01.012</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Della Gala</surname> <given-names>G</given-names>
</name>
<name>
<surname>Dirkx</surname> <given-names>MLP</given-names>
</name>
<name>
<surname>Hoekstra</surname> <given-names>N</given-names>
</name>
<name>
<surname>Fransen</surname> <given-names>D</given-names>
</name>
<name>
<surname>Lanconelli</surname> <given-names>N</given-names>
</name>
<name>
<surname>van de Pol</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Fully automated vmat treatment planning for advanced-stage nsclc patients</article-title>. <source>Strahlentherapie und Onkologie</source> (<year>2017</year>) <volume>193</volume>(<issue>5</issue>):<page-range>402&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00066-017-1121-1</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tseng</surname> <given-names>HH</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Cui</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chien</surname> <given-names>JT</given-names>
</name>
<name>
<surname>Ten Haken</surname> <given-names>RK</given-names>
</name>
<name>
<surname>Naqa</surname> <given-names>IE</given-names>
</name>
</person-group>. <article-title>Deep reinforcement learning for automated radiation adaptation in lung cancer</article-title>. <source>Med Phys</source> (<year>2017</year>) <volume>44</volume>(<issue>12</issue>):<page-range>6690&#x2013;705</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/mp.12625</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>JB</given-names>
</name>
<name>
<surname>Men</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparison between atlas and convolutional neural network based automatic segmentation of multiple organs at risk in non-small cell lung cancer</article-title>. <source>Medicine</source> (<year>2020</year>) <volume>99</volume>(<issue>34</issue>):<page-range>e21800</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/md.0000000000021800</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>YC</given-names>
</name>
<name>
<surname>Tyagi</surname> <given-names>N</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Rimner</surname> <given-names>A</given-names>
</name>
<name>
<surname>Deasy</surname> <given-names>JO</given-names>
</name>
<etal/>
</person-group>. <article-title>Cross-modality (Ct-mri) prior augmented deep learning for robust lung tumor segmentation from small Mr datasets</article-title>. <source>Med Phys</source> (<year>2019</year>) <volume>46</volume>(<issue>10</issue>):<page-range>4392&#x2013;404</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/mp.13695</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname> <given-names>AK</given-names>
</name>
<name>
<surname>Bell</surname> <given-names>MH</given-names>
</name>
<name>
<surname>Nirodi</surname> <given-names>CS</given-names>
</name>
<name>
<surname>Story</surname> <given-names>MD</given-names>
</name>
<name>
<surname>Minna</surname> <given-names>JD</given-names>
</name>
</person-group>. <article-title>Radiogenomics predicting tumor responses to radiotherapy in lung cancer</article-title>. <source>Semin Radiat Oncol</source> (<year>2010</year>) <volume>20</volume>(<issue>3</issue>):<page-range>149&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.semradonc.2010.01.002</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amugongo</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Osorio</surname> <given-names>EV</given-names>
</name>
<name>
<surname>Green</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cobben</surname> <given-names>D</given-names>
</name>
<name>
<surname>van Herk</surname> <given-names>M</given-names>
</name>
<name>
<surname>McWilliam</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Early prediction of tumour-response to radiotherapy in nsclc patients</article-title>. <source>Phys Med Biol</source> (<year>2021</year>) <volume>66</volume>(<issue>22</issue>)<fpage>:S850&#x2013;S850</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1088/1361-6560/ac2f88</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coroller</surname> <given-names>TP</given-names>
</name>
<name>
<surname>Agrawal</surname> <given-names>V</given-names>
</name>
<name>
<surname>Narayan</surname> <given-names>V</given-names>
</name>
<name>
<surname>Hou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Grossmann</surname> <given-names>P</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>SW</given-names>
</name>
<etal/>
</person-group>. <article-title>Radiomic phenotype features predict pathological response in non-small cell lung cancer</article-title>. <source>RADIOTHERAPY AND Oncol</source> (<year>2016</year>) <volume>119</volume>(<issue>3</issue>):<page-range>480&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.radonc.2016.04.004</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dissaux</surname> <given-names>G</given-names>
</name>
<name>
<surname>Visvikis</surname> <given-names>D</given-names>
</name>
<name>
<surname>Da-ano</surname> <given-names>R</given-names>
</name>
<name>
<surname>Pradier</surname> <given-names>O</given-names>
</name>
<name>
<surname>Chajon</surname> <given-names>E</given-names>
</name>
<name>
<surname>Barillot</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Pretreatment f-18-Fdg Pet/Ct radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non-small cell lung cancer: A multicentric study</article-title>. <source>J OF Nucl Med</source> (<year>2020</year>) <volume>61</volume>(<issue>6</issue>):<page-range>814&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2967/jnumed.119.228106</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>T</given-names>
</name>
<name>
<surname>Xin</surname> <given-names>B</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Integrative nomogram of ct imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer</article-title>. <source>Eur Radiol</source> (<year>2019</year>) <volume>29</volume>(<issue>6</issue>):<page-range>2958&#x2013;67</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00330-018-5949-2</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chalkidou</surname> <given-names>A</given-names>
</name>
<name>
<surname>O'Doherty</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Marsden</surname> <given-names>PK</given-names>
</name>
</person-group>. <article-title>False discovery rates in pet and ct studies with texture features: A systematic review</article-title>. <source>PLoS One</source> (<year>2015</year>) <volume>10</volume>(<issue>5</issue>):<elocation-id>e0124165</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0124165</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamashita</surname> <given-names>H</given-names>
</name>
<name>
<surname>Nakagawa</surname> <given-names>K</given-names>
</name>
<name>
<surname>Nakamura</surname> <given-names>N</given-names>
</name>
<name>
<surname>Koyanagi</surname> <given-names>H</given-names>
</name>
<name>
<surname>Tago</surname> <given-names>M</given-names>
</name>
<name>
<surname>Igaki</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors</article-title>. <source>Radiat Oncol (London England)</source> (<year>2007</year>) <volume>2</volume>:<elocation-id>21</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1748-717x-2-21</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luna</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Chao</surname> <given-names>HH</given-names>
</name>
<name>
<surname>Diffenderfer</surname> <given-names>ES</given-names>
</name>
<name>
<surname>Valdes</surname> <given-names>G</given-names>
</name>
<name>
<surname>Chinniah</surname> <given-names>C</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Predicting radiation pneumonitis in locally advanced stage ii-iii non-small cell lung cancer using machine learning</article-title>. <source>Radiotherapy Oncol</source> (<year>2019</year>) <volume>133</volume>:<page-range>106&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.radonc.2019.01.003</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Sahoo</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Predictive performance of different ntcp techniques for radiation-induced esophagitis in nsclc patients receiving proton radiotherapy</article-title>. <source>Sci Rep</source> (<year>2022</year>) <volume>12</volume>(<issue>1</issue>):<fpage>9178</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-022-12898-8</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Cui</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hong</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by ct radiomics and machine learning</article-title>. <source>Med Phys</source> (<year>2022</year>) <volume>49</volume>(<issue>3</issue>):<page-range>1547&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/mp.15451</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramella</surname> <given-names>S</given-names>
</name>
<name>
<surname>Trodella</surname> <given-names>L</given-names>
</name>
<name>
<surname>Mineo</surname> <given-names>TC</given-names>
</name>
<name>
<surname>Pompeo</surname> <given-names>E</given-names>
</name>
<name>
<surname>Stimato</surname> <given-names>G</given-names>
</name>
<name>
<surname>Gaudino</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage iiia-b nsclc treated with combined-modality therapy</article-title>. <source>Int J Radiat oncology biology Phys</source> (<year>2010</year>) <volume>76</volume>(<issue>1</issue>):<page-range>110&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.01.036</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Briere</surname> <given-names>TM</given-names>
</name>
<name>
<surname>Krafft</surname> <given-names>S</given-names>
</name>
<name>
<surname>Liao</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Martel</surname> <given-names>MK</given-names>
</name>
</person-group>. <article-title>Lung size and the risk of radiation pneumonitis</article-title>. <source>Int J Radiat oncology biology Phys</source> (<year>2016</year>) <volume>94</volume>(<issue>2</issue>):<page-range>377&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2015.10.002</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Placidi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Cusumano</surname> <given-names>D</given-names>
</name>
<name>
<surname>Lenkowicz</surname> <given-names>J</given-names>
</name>
<name>
<surname>Boldrini</surname> <given-names>L</given-names>
</name>
<name>
<surname>Valentini</surname> <given-names>V</given-names>
</name>
</person-group>. <article-title>On dose cube pixel spacing pre-processing for features extraction stability in dosiomic studies</article-title>. <source>Physica Med PM an Int J devoted to Appl Phys to Med Biol</source> (<year>2021</year>) <volume>90</volume>:<page-range>108&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejmp.2021.09.010</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>H</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Dosiomics: Extracting 3d spatial features from dose distribution to predict incidence of radiation pneumonitis</article-title>. <source>Front Oncol</source> (<year>2019</year>) <volume>9</volume>:<elocation-id>269</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2019.00269</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ioannidis</surname> <given-names>JP</given-names>
</name>
</person-group>. <article-title>Why most published research findings are false</article-title>. <source>PLoS Med</source> (<year>2005</year>) <volume>2</volume>(<issue>8</issue>):<elocation-id>e124</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pmed.0020124</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambin</surname> <given-names>P</given-names>
</name>
<name>
<surname>Leijenaar</surname> <given-names>RTH</given-names>
</name>
<name>
<surname>Deist</surname> <given-names>TM</given-names>
</name>
<name>
<surname>Peerlings</surname> <given-names>J</given-names>
</name>
<name>
<surname>de Jong</surname> <given-names>EEC</given-names>
</name>
<name>
<surname>van Timmeren</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Radiomics: The bridge between medical imaging and personalized medicine</article-title>. <source>Nat Rev Clin Oncol</source> (<year>2017</year>) <volume>14</volume>(<issue>12</issue>):<page-range>749&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrclinonc.2017.141</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perone</surname> <given-names>CS</given-names>
</name>
<name>
<surname>Cohen-Adad</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Promises and limitations of deep learning for medical image segmentation</article-title>. <source>J Med Artif Intell</source> (<year>2019</year>) <volume>2</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/jmai.2019.01.01</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bitterman</surname> <given-names>DS</given-names>
</name>
<name>
<surname>Selesnick</surname> <given-names>P</given-names>
</name>
<name>
<surname>Bredfeldt</surname> <given-names>J</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Guthier</surname> <given-names>C</given-names>
</name>
<name>
<surname>Huynh</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Dosimetric planning tradeoffs to reduce heart dose using machine learning-guided decision support software in patients with lung cancer</article-title>. <source>Int J Radiat Oncol Biol Phys</source> (<year>2022</year>) <volume>112</volume>(<issue>4</issue>):<fpage>996</fpage>&#x2013;<lpage>1003</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ijrobp.2021.11.009</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname> <given-names>W</given-names>
</name>
<name>
<surname>Niraula</surname> <given-names>D</given-names>
</name>
<name>
<surname>El Naqa</surname> <given-names>I</given-names>
</name>
<name>
<surname>Ten Haken</surname> <given-names>RK</given-names>
</name>
<name>
<surname>Dinov</surname> <given-names>ID</given-names>
</name>
<name>
<surname>Cuneo</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Precision radiotherapy <italic>Via</italic> information integration of expert human knowledge and ai recommendation to optimize clinical decision making</article-title>. <source>Comput Methods programs biomedicine</source> (<year>2022</year>) <volume>221</volume>:<elocation-id>106927</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cmpb.2022.106927</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>